As FDA decision nears, GSK projects 'Shingrix-like' sales for its RSV vaccine prospect

GSK, homing in on a potential world-first vaccine approval in respiratory syncytial virus (RSV), figures its candidate could eventually net billions of dollars each year, executives said Wednesday.